Payment overview · 2025
General Payments
$5,122.05
92 reported records · 22 companies
Healthcare provider profile · identity verified
Leonard Christopher Treanor, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HAMMOND, LA · NPI 1487823506
Verified facts
What the public records show
CMS Open Payments records show Leonard Christopher Treanor, M.D. received $5,122.05 in general payments during 2025 across 92 reported records.
AstraZeneca Pharmaceuticals LP accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Qulipta, Rexulti, Rybelsus, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 287 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 510 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1301 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,712.08 | 53.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $407.15 | 8.0% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $287.75 | 5.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.73 | 5.0% | 6 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $248.17 | 4.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $207.58 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $193.83 | 3.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $155.61 | 3.0% | 30 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $146.48 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $118.97 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.91 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.40 | 0.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.51 | 0.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.80 | 0.7% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $32.77 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.25 | 0.6% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $31.86 | 0.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.30 | 0.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $18.24 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.84 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.91 | 0.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.91 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,762.56 | 88 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,250.00 | 3 |
| Education | $109.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $2,639.43 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $257.53 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $211.67 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $211.23 | 5 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $207.58 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $178.26 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $149.62 | 3 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $146.48 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $139.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $138.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $130.38 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $128.35 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $118.97 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $108.43 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $108.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.83 | 23 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $95.84 | 22 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $84.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.41 | 6 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $32.77 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.01 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1301 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 510 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 202 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 166 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
287 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
510 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 28 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
146 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
166 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
333 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
166 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1301 | 127 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1968 | 258 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1803 | 286 |
| Amlodipine Besylate | Amlodipine Besylate | 1443 | 232 |
| Furosemide | Furosemide | 1328 | 223 |
| Eliquis | Apixaban | 1301 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1201 | 180 |
| Gabapentin | Gabapentin | 1098 | 184 |
| Trazodone Hcl | Trazodone Hcl | 1072 | 155 |
| Metoprolol Succinate | Metoprolol Succinate | 1001 | 149 |
| Memantine Hcl | Memantine Hcl | 906 | 91 |
| Potassium Chloride | Potassium Chloride | 825 | 132 |
| Clopidogrel | Clopidogrel Bisulfate | 762 | 112 |
| Donepezil Hcl | Donepezil Hcl | 713 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 707 | 111 |
| Lisinopril | Lisinopril | 659 | 121 |
| Sertraline Hcl | Sertraline Hcl | 647 | 80 |
| Mirtazapine | Mirtazapine | 640 | 82 |
| Carvedilol | Carvedilol | 636 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 630 | 100 |
| Alprazolam | Alprazolam | 621 | 95 |
| Escitalopram Oxalate | Escitalopram Oxalate | 591 | 89 |
| Losartan Potassium | Losartan Potassium | 564 | 96 |
| Quetiapine Fumarate | Quetiapine Fumarate | 542 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 530 | 79 |
| Famotidine | Famotidine | 513 | 65 |
| Farxiga | Dapagliflozin Propanediol | 510 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 505 | 67 |
| Metformin Hcl | Metformin Hcl | 496 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 479 | 120 |
| Omeprazole | Omeprazole | 438 | 72 |
| Levetiracetam | Levetiracetam | 406 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 387 | 87 |
| Buspirone Hcl | Buspirone Hcl | 354 | 56 |
| Amiodarone Hcl | Amiodarone Hcl | 350 | 47 |
| Meloxicam | Meloxicam | 338 | 64 |
| Entresto | Sacubitril/Valsartan | 333 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 328 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 325 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 69 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 312 | 35 |
| Montelukast Sodium | Montelukast Sodium | 309 | 42 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 293 | 38 |
| Linzess | Linaclotide | 287 | 55 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 280 | 59 |
| Januvia | Sitagliptin Phosphate | 275 | 30 |
| Clonazepam | Clonazepam | 272 | 42 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 268 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 268 | 50 |
| Allopurinol | Allopurinol | 267 | 41 |
| Myrbetriq | Mirabegron | 267 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 261 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 256 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 237 | 80 |
| Aripiprazole | Aripiprazole | 237 | 33 |
| Baclofen | Baclofen | 213 | 44 |
| Sucralfate | Sucralfate | 212 | 27 |
| Olanzapine | Olanzapine | 211 | 28 |
| Divalproex Sodium | Divalproex Sodium | 210 | 29 |
| Risperidone | Risperidone | 210 | 24 |
| Latanoprost | Latanoprost | 205 | 32 |
| Spironolactone | Spironolactone | 203 | 35 |
| Jardiance | Empagliflozin | 202 | 28 |
| Nifedipine Er | Nifedipine | 201 | 28 |
| Simvastatin | Simvastatin | 198 | 25 |
| Atenolol | Atenolol | 180 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 35 |
| Pregabalin | Pregabalin | 171 | 30 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 170 | 21 |
| Ibuprofen | Ibuprofen | 169 | 51 |
| Ozempic | Semaglutide | 166 | 30 |
| Rexulti | Brexpiprazole | 166 | 12 |
| Alendronate Sodium | Alendronate Sodium | 160 | 26 |
| Oxcarbazepine | Oxcarbazepine | 159 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 158 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 156 | 24 |
| Finasteride | Finasteride | 155 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 153 | 24 |
| Tramadol Hcl | Tramadol Hcl | 152 | 54 |
| Novolog Flexpen | Insulin Aspart | 146 | 31 |
| Nystatin | Nystatin | 146 | 64 |
| Xarelto | Rivaroxaban | 146 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 143 | 22 |
| Clonidine Hcl | Clonidine Hcl | 141 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 138 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 133 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 131 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 40 |
| Calcitriol | Calcitriol | 126 | 17 |
| Lactulose | Lactulose | 121 | 35 |
| Cefdinir | Cefdinir | 118 | 91 |
| Bupropion Xl | Bupropion Hcl | 114 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 114 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 112 | 39 |
| Prednisone | Prednisone | 112 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 111 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 22 |
| Megestrol Acetate | Megestrol Acetate | 110 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 108 | 44 |
| Breo Ellipta | Fluticasone/Vilanterol | 106 | 16 |
| Lorazepam | Lorazepam | 106 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 105 | 76 |
| Humalog Kwikpen U-100 | Insulin Lispro | 102 | 20 |
| Primidone | Primidone | 102 | 12 |
| Promethazine Hcl | Promethazine Hcl | 100 | 31 |
| Glimepiride | Glimepiride | 97 | 16 |
| Methocarbamol | Methocarbamol | 93 | 26 |
| Ondansetron Odt | Ondansetron | 93 | 34 |
| Divalproex Sodium Er | Divalproex Sodium | 92 | suppressed |
| Topiramate | Topiramate | 92 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 15 |
| Ezetimibe | Ezetimibe | 89 | 24 |
| Scopolamine | Scopolamine | 88 | suppressed |
| Celecoxib | Celecoxib | 87 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 13 |
| Mounjaro | Tirzepatide | 85 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 62 |
| Ranolazine Er | Ranolazine | 84 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 62 |
| Valsartan | Valsartan | 81 | 12 |
| Ramipril | Ramipril | 80 | suppressed |
| Gemtesa | Vibegron | 79 | 13 |
| Novolog | Insulin Aspart | 79 | 16 |
| Tradjenta | Linagliptin | 79 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 78 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 78 | 61 |
| Ingrezza | Valbenazine Tosylate | 75 | suppressed |
| Lubiprostone | Lubiprostone | 75 | suppressed |
| Glipizide Er | Glipizide | 74 | suppressed |
| Restasis Multidose | Cyclosporine | 74 | suppressed |
| Azithromycin | Azithromycin | 73 | 59 |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Levofloxacin | Levofloxacin | 71 | 58 |
| Vascepa | Icosapent Ethyl | 71 | suppressed |
| Bumetanide | Bumetanide | 69 | 13 |
| Midodrine Hcl | Midodrine Hcl | 69 | 18 |
| Fluconazole | Fluconazole | 68 | 47 |
| Methylprednisolone | Methylprednisolone | 68 | 62 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 11 |
| Temazepam | Temazepam | 68 | 14 |
| Cyclosporine | Cyclosporine | 67 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 65 | suppressed |
| Cilostazol | Cilostazol | 64 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 18 |
| Cephalexin | Cephalexin | 62 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 61 | 37 |
| Solifenacin Succinate | Solifenacin Succinate | 59 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 17 |
| Lumigan | Bimatoprost | 58 | suppressed |
| Mupirocin | Mupirocin | 56 | 32 |
| Amantadine | Amantadine Hcl | 55 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 54 | suppressed |
| Novolin R | Insulin Regular, Human | 54 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 53 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 52 | 23 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Irbesartan | Irbesartan | 51 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Estradiol | Estradiol | 50 | 13 |
| Terazosin Hcl | Terazosin Hcl | 49 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 48 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 48 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Restasis | Cyclosporine | 46 | 15 |
| Armour Thyroid | Thyroid,pork | 45 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Rivastigmine | Rivastigmine | 45 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Ketoconazole | Ketoconazole | 44 | 16 |
| Constulose | Lactulose | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 42 | suppressed |
| Metolazone | Metolazone | 42 | suppressed |
| Humulin R | Insulin Regular, Human | 41 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 13 |
| Levemir Flexpen | Insulin Detemir | 41 | 12 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 40 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 39 | suppressed |
| Ubrelvy | Ubrogepant | 39 | suppressed |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 38 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 37 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 25 |
| Glipizide | Glipizide | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 11 |
| Bupropion Hcl | Bupropion Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Xiidra | Lifitegrast | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Humalog | Insulin Lispro | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 23 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Mirabegron Er | Mirabegron | 21 | 14 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 15 |
| Cyclosporine Modified | Cyclosporine, Modified | 18 | suppressed |
| Daptomycin | Daptomycin | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | 14 |
| Vyvanse | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Abilify Maintena | Aripiprazole | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Permethrin | Permethrin | 17 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Nystop | Nystatin | 14 | 11 |
| Roflumilast | Roflumilast | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Pulmicort Flexhaler | Budesonide | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,122.05 · 92 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CLOTTRIEVER BOLD CATHETER, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, FUROSCIX, JARDIANCE, KRYSTEXXA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PURAPLY WOUND MATRIX, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, Senza, UROLIFT, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error